Lyell Immunopharma Fails Nasdaq Listing Standards
Ticker: LYEL · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
TL;DR
Lyell Immunopharma is getting kicked off Nasdaq for low stock price.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on January 23, 2025, to report its failure to meet the continued listing standards of the Nasdaq Stock Market. The company was notified that it did not meet the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Why It Matters
This filing indicates Lyell Immunopharma may be delisted from the Nasdaq, potentially impacting its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — Failure to meet listing standards suggests significant financial distress or market concerns about the company's future, increasing delisting risk.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Listing Exchange
- The Nasdaq Capital Market (company) — Specific Market Tier
- January 23, 2025 (date) — Date of Report
FAQ
What specific Nasdaq listing rule did Lyell Immunopharma fail to meet?
Lyell Immunopharma failed to meet the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
When did Lyell Immunopharma become aware of this non-compliance?
The filing reports the event as of January 23, 2025, indicating this is the date of awareness or notification.
What is the company's principal executive office address?
The company's principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
What is Lyell Immunopharma's IRS Employer Identification Number?
Lyell Immunopharma's IRS Employer Identification Number is 83-1300510.
What is the SEC file number for Lyell Immunopharma?
The SEC file number for Lyell Immunopharma is 001-40502.
Filing Stats: 1,083 words · 4 min read · ~4 pages · Grade level 16.1 · Accepted 2025-01-24 16:39:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq
- $1.00 — Company's common stock had closed below $1.00 per share, the minimum closing bid pric
Filing Documents
- d884359d8k.htm (8-K) — 27KB
- 0001193125-25-012249.txt ( ) — 143KB
- lyel-20250123.xsd (EX-101.SCH) — 3KB
- lyel-20250123_lab.xml (EX-101.LAB) — 17KB
- lyel-20250123_pre.xml (EX-101.PRE) — 11KB
- d884359d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: January 24, 2025 By: /s/ Matthew Lang Matthew Lang Chief Business Officer